Martin, M
Disclosures: Simone Fonte: Nothing to Disclose, Marie Laure Plissonnier: Nothing to Disclose, Maud Michelet: Nothing to Disclose, Matthieu Blanchet: Nothing to Disclose, Patrick Labont: Nothing to Disclose, Andrew Vaillant: Replicor Inc.: Employee, Replicor Inc.: Stock privately held company, Massimo Levrero: CLS Behring: Speaking and Teaching, Roche: Grant/Research Support, Ipsen: Grant/Research Support, Gilead: Speaking and Teaching, Gilead: Travel grant, Abbvie: Travel Grant, Inventiva: Travel grant, MSD: Travel grant 416 SAFETY PROFILE OF TOBEVIBART (VIR-3434) AND ELEBSIRAN (VIR-2218) FOR THE TREATMENT OF CHRONIC HEPATITIS B AND DELTA (CHB AND CHD) Alina Jucov 1 Edward Gane 2 Man-Fung Yuen 3 Kosh Agarwal 4 Anca Streinu-Cercel 5 Young-Suk Lim 6 Keith Boundy 7 Cara Pilowa 7 Michael Chattergoon 7 Andre Arizpe 7 Vaidehi Thanawala 7 Shuli Yu 7 Pan Wu 7 Yimeng Lu 7 Todd Correll 7 Tarik Asselah 8 , 1 ARENSIA Exploratory Medicine GmbH, 2 Auckland Clinical Studies, 3 The University of Hong Kong, 4 King's College Hospital, 5 National Institute for Infectious Diseases, 6 Asan Medical Center, 7 Vir Biotechnology, Inc., 8 Hpital Beaujon Background: Tobevibart (VIR-3434) is an investigational fragment crystallizable (Fc)-engineered human monoclonal antibody that binds to the antigenic loop present in all forms of hepatitis B surface antigen (HBsAg)
Lets talk about the safest, least disruptive way to get you back on track.
These medications should be a jump start toward a healthy lifestyle with diet and exercise, not a substitute, says the lead author, John Gabriel Horneff III, MD, an associate professor of orthopedic surgery at the University of Pennsylvania in Philadelphia
10.1006/abbi.1995.9932 53 SheikhhosseinF.BorazjaniM.JafariA.AskariM.VataniyanE.GholamiF.et al (2021)
